1) dp π coordination bond in simple compounds>In the H 2 SO 4
Dp π coordination bond (feedback bond) in coordination compounds
Time of Update: 2021-06-18
In the complex formed by cyanide and transition metal , the lone electron on C in CN - coordinates to the metal hybrid empty orbital to form .
J Clin Oncol: Issue III | Pym monoanti-anti-ipi mono-anti-treatment PD-L1 TPS≥50% metastasis NSCLC (KEYNOTE-598)
Time of Update: 2021-02-12
Pym monotherapy is a standard first-line treatment for metastasis non-small cell lung cancer (NSCLC) with a programmed death ligation ≥ 1 (PD-L1) tumor ratio score (TPS) of 50% and inoperable drive gene mutations. it is not clear whether
Science reveals a new neuroloop DP/DTT-DMH with a faster heartbeat at chronic stress.
Time of Update: 2020-07-22
The researchers did find that the central body temperature, heart rate, and average arterial pressure of rats after chronic stress all increased, and these sympathetic nerve symptoms disappeared after inhibiting the activity of DP/DTT neurons.
Serum TP is closely related to inflammatory response and poor prognosis in patients with severe TBI
Time of Update: 2020-06-27
TBI prognostic variables, including acute lung injury (ALI), acute traumatic clotting disease (ATC), progressive intracranial hemorrhagic lesions (PHI) and post-traumatic brain infarction (PTCI), 6 months of death, and 6 months of poor prognosis (i.e. GOS score is 1-3).
New epilepsy drug dp-vpa jointly developed by Enhua pharmaceutical and d-pharm in Israel has entered the phase III clinical trial
Time of Update: 2020-04-03
Jiangsu Enhua Pharmaceutical Co., Ltd
said in the morning of February 14 that the dp-vpa innovative drug jointly developed by Enhua pharmaceutical and Israeli d-pharm
The clinical application of dp-vpa, a class 1 antiepileptic drug of Enhua Pharmaceutical Co., Ltd. has been completed
Time of Update: 2015-04-13
According to the information on April 13 on the website of CFDA, the clinical application status of dp-vpa APIs and tablets of class 1 new drug of Enhua Pharmaceutical Co., Ltd
Class 1.1 new drug dp-vpa of Enhua pharmaceutical was approved for clinical application
Time of Update: 2015-03-24
On the one hand, Enhua pharmaceutical has the leading advantage in the domestic central nervous drug market, but on the other hand, the research and development prospect of dp-vpa is not clear enough.
Class 1 antiepileptic drug dp-vpa of Enhua pharmaceutical has completed technical approval
Time of Update: 2015-03-20
According to the information on the website of CFDA on March 20, the clinical application status of dp-vpa API and tablet for class 1 new drug of Enhua Pharmaceutical (002262.
Dp-vpa, a new drug jointly developed by Enhua pharmaceutical and Israel, is in clinical research stage
Time of Update: 2014-11-12
According to the public information, the preventive and therapeutic effects of etacalin and its derivatives on pulmonary hypertension have been patented in China.
